Abbott Laboratories (NYSE:ABT) Rating Increased to Outperform at Wolfe Research

Abbott Laboratories (NYSE:ABT) was upgraded by analysts at Wolfe Research from a “peer perform” rating to an “outperform” rating in a research report issued on Thursday, Marketbeat reports. The brokerage presently has a $130.00 target price on the healthcare product maker’s stock. Wolfe Research’s price target points to a potential upside of 17.20% from the stock’s current price.

A number of other analysts have also weighed in on the stock. Robert W. Baird started coverage on shares of Abbott Laboratories in a research note on Wednesday, July 1st. They issued an “outperform” rating and a $121.00 price target for the company. Royal Bank Of Canada reissued an “outperform” rating and set a $130.00 target price on shares of Abbott Laboratories in a report on Friday, July 17th. Daiwa Securities Group downgraded Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 target price for the company. in a research report on Wednesday, April 22nd. Weiss Ratings raised Abbott Laboratories from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, August 6th. Finally, TD Cowen reiterated a “buy” rating and set a $115.00 price target on shares of Abbott Laboratories in a research report on Friday, July 17th. Three investment analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $118.67.

Abbott Laboratories Trading Up 1.1%

NYSE:ABT opened at $110.92 on Thursday. The stock has a market cap of $191.93 billion, a price-to-earnings ratio of 35.90, a PEG ratio of 2.12 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a 1 year low of $81.97 and a 1 year high of $137.49. The business has a fifty day moving average of $96.86 and a 200-day moving average of $99.73.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share for the quarter, topping the consensus estimate of $1.28 by $0.03. The business had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company’s quarterly revenue was up 13.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. Equities analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Institutional Investors Weigh In On Abbott Laboratories

A number of institutional investors have recently bought and sold shares of the business. Nia Impact Advisors LLC increased its position in Abbott Laboratories by 2.2% in the 2nd quarter. Nia Impact Advisors LLC now owns 3,706 shares of the healthcare product maker’s stock valued at $504,000 after buying an additional 79 shares in the last quarter. Riggs Asset Managment Co. Inc. boosted its holdings in Abbott Laboratories by 9.3% in the second quarter. Riggs Asset Managment Co. Inc. now owns 1,031 shares of the healthcare product maker’s stock worth $140,000 after acquiring an additional 88 shares in the last quarter. GHP Investment Advisors Inc. grew its stake in Abbott Laboratories by 0.3% in the fourth quarter. GHP Investment Advisors Inc. now owns 29,411 shares of the healthcare product maker’s stock valued at $3,685,000 after acquiring an additional 92 shares during the period. Eley Financial Management Inc increased its holdings in shares of Abbott Laboratories by 0.9% during the fourth quarter. Eley Financial Management Inc now owns 10,817 shares of the healthcare product maker’s stock valued at $1,355,000 after acquiring an additional 92 shares in the last quarter. Finally, Kelleher Financial Advisors raised its position in shares of Abbott Laboratories by 2.9% during the third quarter. Kelleher Financial Advisors now owns 3,301 shares of the healthcare product maker’s stock worth $442,000 after purchasing an additional 93 shares during the period. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.